Statistics for A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Total visits
| views | |
|---|---|
| A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study | 264 |
Total visits per month
| views | |
|---|---|
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
File Visits
| views | |
|---|---|
| nihms734272.pdf | 380 |
Top country views
| views | |
|---|---|
| United States | 192 |
| Germany | 17 |
| Sweden | 9 |
| Ukraine | 8 |
| Russia | 6 |
| China | 4 |
| United Kingdom | 3 |
| Canada | 2 |
| Poland | 2 |
| France | 1 |
| India | 1 |
| Italy | 1 |
| Malaysia | 1 |
| Philippines | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 48 |
| Fairfield | 32 |
| Ann Arbor | 24 |
| Kiez | 15 |
| Houston | 12 |
| Cambridge | 9 |
| White Plains | 9 |
| Stockholm | 8 |
| Jacksonville | 7 |
| Kiev | 7 |
| Beijing | 3 |
| Saint Petersburg | 3 |
| Gunzenhausen | 2 |
| Henryk | 2 |
| Moscow | 2 |
| San Francisco | 2 |
| Toronto | 2 |
| Washington | 2 |
| Abingdon | 1 |
| Baltimore | 1 |
| Brooklyn | 1 |
| Grùmolo | 1 |
| Indiana | 1 |
| Motala | 1 |
| Paris | 1 |
| Philadelphia | 1 |
| Scottsdale | 1 |
| Seremban | 1 |